PZ0362

CP-640186 hydrochloride

≥95% (HPLC)

• Sinónimos: (3R)-Anthracen-9-yl-[3-(morpholine-4-carbonyl)-[1,4′]bipiperidinyl-1′-yl]-methanone hydrochloride, CP 640186 hydrochloride, CP640186 hydrochloride, [(3R)-1′-(9-Anthracenylcarbonyl)[1,4′-bipiperidin]-3-yl]-4-morpholinyl-methanone hydrochloride
• Fórmula empírica (notación de Hill): C₃₀H₃₅N₃O₃ · HCl
• Número de CAS: 591778-70-0
• Peso molecular: 522.08
• Número MDL: MFCD28167776
• Código UNSPSC: 41121800
• NACRES: NA.77

Propiedades

• Nivel de calidad: 100
• Análisis: ≥95% (HPLC)
• formulario: powder
• condiciones de almacenamiento: desiccated
• color: white to beige
• solubilidad: H₂O: 2 mg/mL, clear (warmed)
• temp. de almacenamiento: room temp
• cadena SMILES: O=C(C1=C2C=CC=CC2=CC3=CC=CC=C31)N(CC4)CCC4N5C[C@H](C(N6CCOCC6)=O)CCC5.[H]Cl
• InChI: 1S/C30H35N3O3.ClH/c34-29(32-16-18-36-19-17-32)24-8-5-13-33(21-24)25-11-14-31(15-12-25)30(35)28-26-9-3-1-6-22(26)20-23-7-2-4-10-27(23)28;/h1-4,6-7,9-10,20,24-25H,5,8,11-19,21H2;1H/t24-;/m1./s1
• Clave InChI: DUBNXJIOBFRASV-GJFSDDNBSA-N

Descripción

Aplicación

CP-640186 hydrochloride has been used as an allosteric acetyl-CoA carboxylase (ACC) inhibitor (ACCi) for pharmacological inhibition of lipogenesis to determine if fatty acid synthesis is essential for brown adipose tissue (BAT) whitening. It has also been used as an inhibitor of mammalian acetyl-CoA carboxylase (mACC1/2) to study its effect on meropenem potency against the persisters from multiple pathogens, including B. thailandensis, P. aeruginosa, S.Typhimurium, and attenuated Y. pestis.

Acciones bioquímicas o fisiológicas

CP-640186 is a potent and orally active acetyl-CoA carboxylase 1/2 (ACC-alpha/beta, ACC1/2) inhibitor (IC50 ~50 nM) that targets the carboxyltransferase (CT) domain at the ACC dimer interface (via tight interactions with the putative biotin-binding site) in a reversible manner, uncompetitive with respect to ATP, and non-competitive with respect to bicarbonate, acetyl-CoA, and citrate. CP-610431 inhibits fatty acid (FA) synthesis, triglyceride (TG) synthesis, TG and apoB secretion (IC50 = 1.6, 1.8, 3.0, and 5.7 μM, respectively), but not cholesterol synthesis or apoC3 secretion in HepG2 cells (ACC1), as well as stimulates FA oxidation in C2C12 cells (ACC2) and in rat epitrochlearis muscle strips (EC50 = 57 nM and 1.3 μM, respectively). Oral administration is shown to inhibit FA synthesis in rats, CD1 mice, and ob/ob mice (ED50 = 13, 11, and 4 mg/kg, respectively) and stimulate rat whole body FA oxidation (ED50 ∼30 mg/kg) in vivo.

Información de seguridad

• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3